How Long Does It Take to Get Endometrial Biopsy Results?

Most endometrial biopsy results come back within seven to fourteen days, though the timeline can stretch to three weeks or longer depending on what the pathologist finds under the microscope. The wait reflects real laboratory work: your tissue sample goes through several processing steps before a pathologist can examine it and issue a report. Understanding what drives those timelines, and what can slow them down, makes the wait a bit more manageable.

What Happens to Your Sample After the Biopsy

Once your doctor collects the tissue, it goes into a small container of preservative fluid and is sent to a pathology laboratory. The journey from collection to final report involves distinct stages, and on average specimens spend about 70% of their total turnaround time inside the laboratory itself, with the rest split between transport and results communication. That laboratory time is where most of the waiting happens.

Inside the lab, the tissue first sits in a fixative solution, usually formalin, for several hours to preserve its structure. After fixation, a technician embeds the tissue in paraffin wax, slices it into sections thinner than a human hair, and mounts those sections on glass slides. The slides are then stained so that cells and tissue structures become visible under a microscope. For a straightforward case, this processing alone takes two to three days.

A pathologist then examines the stained slides, looking at the glandular architecture, the appearance of individual cells, and how the tissue relates to what is expected given your hormonal status and menstrual cycle phase. The endometrium changes dramatically throughout the menstrual cycle, thickening more than tenfold during the proliferative phase alone, so the pathologist needs clinical context to interpret what they see.¹ If the tissue looks routine, the pathologist can finalize their report within a day or two of reviewing it. That puts the total at roughly one to two weeks from the day of your biopsy.

Why Some Results Take Longer

The one-to-two-week window is a baseline, not a guarantee. Several things can push results past that range.

Special stains: If the pathologist sees something that needs further characterization, they may order immunohistochemical stains. These are additional tests that highlight specific proteins in the tissue and help distinguish, for example, a benign process from a precancerous one. Each round of special staining adds days to the timeline.
Second opinions: Unusual or borderline findings sometimes prompt a pathologist to request a colleague’s review. Some labs routinely have a second pathologist sign off on any result involving atypia or suspected cancer. This peer-review step is a quality measure, but it adds time.
Lab volume: Pathology laboratories handle thousands of specimens across surgical, dermatologic, and gynecologic cases. A backlog from high volume or staffing shortages can delay any individual result by several days.
Holiday and weekend closures: Most pathology labs operate on business days. A biopsy taken on a Thursday may not begin processing until the following Monday, effectively adding a few days before the clock even starts.

If three weeks have passed without a word from your doctor’s office, it is reasonable to call and ask. Sometimes results are sitting in the system waiting to be communicated rather than still pending at the lab.

When the Biopsy Comes Back “Insufficient”

One outcome that catches people off guard is a result that reads “insufficient for diagnosis” or “inadequate sample.” This means the pathologist did not have enough tissue to make a reliable determination. It does not mean something is wrong with you; it means the procedure did not capture enough endometrial tissue to evaluate.

This is more common than most people expect. In a large study of over 27,000 patients, the overall rate of insufficient office biopsies was about 12%, but the rate varied sharply by age group. Among premenopausal patients, roughly 8% of biopsies were insufficient, while among postmenopausal patients the rate jumped to about 29%.² A separate, smaller study found a similar pattern: menopausal status and a thin endometrial lining were the strongest predictors of getting an insufficient sample.³

The reason is straightforward. After menopause, estrogen levels drop and the endometrium thins. A thin lining simply has less tissue for the sampling device to collect. Uterine fibroids can also make it harder to reach the endometrial cavity effectively, and in the large study mentioned above, fibroids were associated with higher insufficiency rates in both pre- and postmenopausal groups.²

An insufficient result does not necessarily mean you need another biopsy right away. Your doctor will weigh your symptoms, risk factors, and imaging findings. In some cases, a thin lining on ultrasound in a postmenopausal woman with an insufficient biopsy is itself reassuring. In other cases, your doctor may recommend a dilation and curettage (D&C), which obtains a larger tissue sample under sedation and has a near-100% sample adequacy rate.

How the Biopsy Method Affects What You Learn

Most office-based endometrial biopsies use a thin, flexible suction device called a Pipelle. It is quick, does not require anesthesia, and for most situations produces results that are highly reliable. One study comparing Pipelle biopsy to D&C found a diagnostic agreement rate of about 98%, with a sensitivity above 94% for detecting endometrial pathologies.⁴

That said, the Pipelle is not perfect in every clinical scenario. In a study of women being treated for early-stage endometrial cancer with hormonal therapy, aspiration biopsy agreed with D&C findings only about 39% of the time, and nearly half of the aspiration samples were insufficient for evaluation.⁵ That was a very specific clinical setting, not the typical screening scenario, but it illustrates why doctors sometimes go straight to a D&C when the stakes are high or when an office biopsy has already failed to produce enough tissue.

For most women being evaluated for abnormal bleeding, an office Pipelle biopsy is the standard first step and is considered highly sensitive for detecting significant pathology including cancer.⁶ When results come back from a Pipelle biopsy and show adequate tissue, you can generally trust the findings.

How You Will Get Your Results

The way results reach you depends on your healthcare system and your doctor’s preferences. Some offices call patients with results regardless of whether they are normal or abnormal. Others call only for abnormal results and send a letter or portal message for normal findings. Increasingly, results are released automatically through online patient portals, sometimes before your doctor has had a chance to review and explain them.

Getting results through a portal can be a mixed experience. Research on patient portals shows that seeing normal results online tends to feel emotionally neutral for most people. But when results are abnormal, more than half of patients in one study reported confusion, concern, anxiety, or frustration upon seeing the information before speaking with a clinician.⁷ Pathology reports are written in medical terminology, and phrases like “disordered proliferative endometrium” or “complex hyperplasia without atypia” can sound alarming to someone without context.

If your portal shows results before your doctor calls, and the language is confusing, resist the urge to interpret it through internet searches. Ask your doctor’s office to walk you through the findings. Even a result that sounds concerning in pathology-speak may be entirely benign.

What the Results Might Say

Endometrial biopsy results generally fall into a few broad categories. Understanding the landscape helps make the waiting period less frightening.

Normal or physiologic endometrium: The tissue matches what is expected for where you are in your menstrual cycle or menopausal status. Proliferative endometrium, secretory endometrium, and atrophic endometrium (common after menopause) are all normal findings.
Disordered proliferative endometrium: The lining shows irregular growth but no worrisome changes. This is common in women with irregular cycles or hormonal imbalances and is generally treated with hormonal medication.
Endometrial polyp: A benign overgrowth that can cause abnormal bleeding. Often managed with removal.
Hyperplasia without atypia: The lining is thicker than normal with more glandular tissue, but the cells themselves look normal. This is usually treated with progesterone therapy and monitoring.
Hyperplasia with atypia: The thickened lining contains cells that look abnormal under the microscope. This is considered a precancerous condition that warrants closer attention.
Endometrial carcinoma: Cancer cells are present in the tissue sample.

Histopathological evaluation of endometrial biopsy tissue remains the standard method for distinguishing benign findings from premalignant and malignant ones.⁸ Most biopsies return benign results. But even a benign finding is valuable, because it either explains your symptoms or rules out something serious.

Managing the Anxiety of Waiting

Waiting for biopsy results is genuinely stressful for many women, and that stress is not just anecdotal. A study of women undergoing investigation for suspected endometrial cancer found that about a third had significant anxiety levels. Women who felt they had not received enough information before their clinic visit had substantially higher anxiety scores than those who felt well-informed.⁹ That connection between information and anxiety is worth noting: asking questions before and after your biopsy, and understanding the general timeline, genuinely helps.

If you find the wait unbearable, calling your doctor’s office at the two-week mark is perfectly appropriate. Most offices expect these calls. You can also ask at the time of your biopsy how results are typically communicated and what the expected turnaround is, so you have a concrete timeline to work with rather than an open-ended wait.

When an Abnormal Result Leads to More Testing

An abnormal biopsy result does not always mean the worst-case scenario. The biopsy is a sampling tool, and like any sampling tool, it captures a piece of the picture. Further steps depend on what the pathologist found.

For hyperplasia with atypia, the finding carries real clinical weight because it sometimes understates what is actually happening in the uterus. In one study of 44 patients who had surgery after being diagnosed with atypical hyperplasia on biopsy, about 48% had their diagnosis confirmed at surgery, but roughly 34% turned out to have endometrial cancer in the full hysterectomy specimen.¹⁰ This is why atypical hyperplasia often leads to a recommendation for hysterectomy rather than continued monitoring alone, especially in women who have completed childbearing.

For hyperplasia without atypia, the approach is usually more conservative. Progesterone therapy and follow-up biopsies at three to six month intervals are common. For a cancer diagnosis on biopsy, the next steps typically involve imaging, possibly additional blood work, and referral to a gynecologic oncologist for surgical planning and staging.

For benign results in the context of ongoing abnormal bleeding, your doctor may still pursue additional evaluation, such as a saline-infusion sonogram or hysteroscopy, to look for structural causes like polyps or fibroids that the biopsy might not have captured. In postmenopausal women with bleeding, an endometrial biopsy is recommended as part of the workup even when ultrasound findings appear normal, because the biopsy picks up pathology that imaging can miss.⁶

Why Postmenopausal Women Face a Different Experience

If you have gone through menopause, the endometrial biopsy experience differs in several ways. The procedure itself can be more uncomfortable because the cervical canal may have narrowed, and as noted earlier, the thinner endometrial lining makes insufficient samples more likely. Postmenopausal status was the single strongest predictor of an insufficient biopsy in the large study cited above, with adjusted odds roughly five times higher than for premenopausal women.²

The clinical significance of findings also shifts after menopause. Any bleeding after menopause warrants investigation, and the threshold for concern is lower. Women taking tamoxifen for breast cancer, for instance, should undergo hysteroscopy-guided biopsy if their endometrial lining measures thicker than 4 mm on ultrasound.⁶ The waiting period for results feels different too, because the reason for the biopsy in a postmenopausal woman is more often to rule out cancer specifically, which raises the emotional stakes.

If you are postmenopausal and your biopsy comes back insufficient, discuss with your doctor whether the result combined with your ultrasound findings is enough to provide reassurance, or whether a D&C is the next appropriate step. An insufficient result in this population is not automatically reassuring and should not be treated as a clean bill of health without further clinical context.